Naveen Pemmaraju, MD

Articles

Dr. Pemmaraju on a New Era of Treatment Strategies in BPDCN

November 4th 2020

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

October 8th 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Dr. Pemmaraju the Need to Develop Novel Therapies in MPNs

September 15th 2020

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Dr. Pemmaraju on the Challenges of Targeting TP53 Mutations in MDS/AML

June 9th 2020

Naveen Pemmaraju, MD, discusses the challenges of targeting TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Dr. Pemmaraju on the Need for Collaboration in Myelofibrosis

April 14th 2020

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Dr. Pemmaraju on Methods to Treat Anemia in MPNs

February 27th 2020

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Dr. Pemmaraju on the Ongoing Trial of Tagraxofusp in Myelofibrosis

August 30th 2019

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.

Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

August 10th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

July 24th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis

December 13th 2017

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

x